Benign Conditions

The recently published findings may open new avenues for treating urinary tract infections.

The authors of a recently published study have found that bariatric surgery may provide a significant benefit beyond dramatic weight loss.

New findings based on pharmacy claims data show just how adherent patients are to a thiazide, alkali citrate, and allopurinol.

A large, randomized trial provides a head-to-head comparison of late complications involving the two approaches to BPH.

New study data suggest an answer to the problem of managing stones in pregnant women.

The first clinical trial of a novel ultrasound technology shows that it can safely reposition stones in situ to make them more amenable to natural passage and treatment.

Urology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas-an information-packed, condensed summary of the top papers and presentations.

A two-drug treatment regimen works better than monotherapy for incontinent overactive bladder patients, researchers reported at the AUA annual meeting in New Orleans.

Use of mesh in the treatment of pelvic organ prolapse is increasing, despite FDA warnings about its risks.

A large, multicenter study “definitively demonstrates” the treatment’s infectiveness, one expert says.

Other products featured include: Radiosurgery collimator allows treatment of broad rang of tumors and Phi prostate cancer test and more.

Greater use of culture-directed care represents an opportunity to improve management of women with uncomplicated UTIs, researchers say.

Products in the pipeline for prostate cancer, bladder cancer, and much more.

An experimental drug that stabilizes a protein protects human bladder cells against a major UTI pathogen, researchers say.

A patient follow-up report shows promising mid-term results from five German urology centers that implemented the prostatic urethral lift (UroLift System, NeoTract, Inc.) to alleviate symptomatic BPH in patients suffering from mild, moderate, and even severe obstruction.

Laser photoselective vaporization prostatectomy using a 180W 532-nm lithium triborate laser (GreenLight XPS-180W laser system, American Medical Systems) is a safe and efficient option for treating BPH in men at high risk for surgical complications, according to findings from a large, international retrospective analysis.

In this Coding Q&A column, the Painters discuss the tricky question of whether you can bill for stone prevention counseling, and also answer a question about whether you can bill two instillation codes (51700) for one appointment.

Other products featured include a spacer system to protect men undergoing PCa radiotherapy, a pelvic floor exercise app, and more.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

Caroline Rhea and Dr. Mueller speak about the steps Doctors can take to help OAB patients, from recognizing the various symptoms and behaviors of a potential OAB patient to the treatment options available for different types of OAB.

The study shows a wide discrepancy between the least and most expensive ways to treat the common prostate condition.

The FDA has approved ceftazidime-avibactam (AVYCAZ) for two indications, including treatment of adults with complicated urinary tract infections who have limited or no alternative treatment options.

Uroplasty, Inc. announced that Cigna has written a positive coverage policy for percutaneous tibial nerve stimulation delivered via Uroplasty's Urgent PC neuromodulation system for treatment of overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.

Despite a recent study’s promise, downsides to the procedure remain, according to one of the study’s authors.

Analyses of data from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project are providing understanding on trends in utilization of simple prostatectomy for treatment of symptomatic BPH and addressing the gap in information about its outcomes.